CZEREPAK ELIZABETH

CIK 00012635008 companiesGAITHERSBURG, MD

SEC Profile

Transactions

Companies

Filings

CIK

0001263500

Recent Transactions

19 trades

Award
DELCATH SYSTEMS, INC.$DCTH
Stock Option (right to buy)
2024-05-23+22,500→ 22,500 total
Award
DELCATH SYSTEMS, INC.$DCTH
Stock Option (Right to Buy)
2023-06-12+19,682→ 19,682 total
Award
Scilex Holding Co$SCLX
Nonstatutory Stock Option (right to buy)
2023-01-17+350,000→ 350,000 total
Award
Sorrento Therapeutics, Inc.$SRNE
Stock Option (right to buy)
2022-05-18+350,000→ 350,000 total
Award
DELCATH SYSTEMS, INC.$DCTH
Stock Options
2022-05-04+9,000→ 9,000 total
Award
Sorrento Therapeutics, Inc.$SRNE
Stock Option (right to buy)
2021-11-18+100,000→ 100,000 total
Award
DELCATH SYSTEMS, INC.$DCTH
Stock Option (right to buy)
2021-08-05+9,000→ 9,000 total
Award
DELCATH SYSTEMS, INC.$DCTH
Stock Option (right to buy)
2020-11-23+20,000→ 20,000 total
Award
SPECTRUM PHARMACEUTICALS INC
Stock Option (Right to Buy)
2020-06-18+60,000→ 60,000 total
Award
SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
2020-06-18+30,000→ 40,000 total
Award
SPECTRUM PHARMACEUTICALS INC
Stock Option (Right to Buy)
2019-06-20+20,000→ 20,000 total
Award
SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
2019-06-20+10,000→ 10,000 total
Award
Altimmune, Inc.$ALT
Stock Option (option to buy)
2017-05-04+18,727→ 18,727 total
Award
Altimmune, Inc.$ALT
Stock Option (option to buy)
2017-05-04+178,595→ 178,595 total
Award
AFFYMAX INC
Stock Option (Right to Buy)
2007-05-31+2,500→ 2,500 total
Award
MiddleBrook Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2005-05-25+20,000→ 20,000 total
Conversion
MiddleBrook Pharmaceuticals, Inc.
Common Stock
2003-10-22+2,428,549→ 2,428,549 total
Conversion
MiddleBrook Pharmaceuticals, Inc.
Series E Convertible Preferred Stock
2003-10-22−4,444,444→ 0 total
Award
MiddleBrook Pharmaceuticals, Inc.
Stock Option (right to buy)
2003-10-16+13,661→ 13,661 total

Companies

Recent Filings

Address

19 FIRSTFIELD ROAD, SUITE 200

GAITHERSBURG, MD, 20878

View on SEC.gov